医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

2015 Q4 Index Closes with Historically High Demand

2016年02月19日 PM10:00
このエントリーをはてなブックマークに追加


 

ROCHELLE PARK, N.J.

ZRG Partners has announced the findings for the fourth quarter Global Life Sciences Hiring Index. Posted hiring activity levels are nearly 30% higher than a year ago.

Outsourcing Services continues to show expansion, steadily increasing hiring levels over 30% since the beginning of the year.

ZRG European President and Global Practice Head of Life Sciences, Adam El Din commented, “Commercial positions will likely continue to shrink in the near future, driven down by industry mergers; the expiration of blockbuster drug patents; and a shift toward flexible, regional, and specialized sales teams.”

David Fortier, Managing Director – Global Life Sciences added, “While the quarterly changes do not reflect a consistent upward trend, the growth from the previous year and overall hiring levels show confidence across virtually all sectors and geographies. This strength results in part from exciting new science and a willing investment base for both established and new companies to pursue these new therapies.”

About ZRG Partners

ZRG Partners, LLC is a global authority on talent management in the Life Sciences, Pharmaceutical and Medical Device markets. ZRG provides its clients with specialized global market expertise in executive recruitment, consulting and advisory work with a focus on data and analytics to drive great business decisions.

The Global Life Sciences Hiring Index analysis utilizes a proprietary algorithm that looks at hiring within selected benchmark companies in three distinct segments. The companies in the index generate over $630 billion in revenues and employ over 1.5 million people globally. ZRG Partners conducts extensive direct market research in developing the data that drives the Index.

For more information about ZRG please go to zrgpartners.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160219005426/en/

CONTACT

For press requests or for permission to use this data in other media
form:
ZRG Partners
Adam
El Din
, +41-22-319-3304
European President and Global Practice
Head of Life Sciences in Switzerland
or
David
Fortier
, +1-202-525-1341
Managing Director in the USA

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表
  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″
  • Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
  • Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
  • 武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果